Nick Tate
Angel Investor @ GSK NEXT
London, United Kingdom
Nick Tate is a seed investor at GSK NEXT in London focused on Health Care and Dental. Nick is the VP Global Digital Innovation at GSK Consumer Healthcare – a role which encompasses anything from accelerating connected devices, platforms and business models to new brand creation and future fit high growth opportunities. With a career spanning agencies, start-ups, innovation businesses and consultancies, Nick has a passion forhuman-centered design, experience-lead brand building and placing empathy (and data) at the heart of every decision of the creative process.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Nick Tate invests in
Stages Nick Tate invests in
Countries Nick Tate invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 8 (67%)
- Dental 4 (33%)
- Wellness 4 (33%)
- Life Science 2 (17%)
- Biotechnology 2 (17%)
Stage
- Seed 3 (25%)
- Funding Round 3 (25%)
- Non-equity Assistance 3 (25%)
- Grant 2 (17%)
- Pre-Seed 1 (8%)
Country
- United States 6 (50%)
- Denmark 1 (8%)
- Australia 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Oral Genome is a health and wellness company for dental services. | Seed / Dec 01, 2022 | ||
| Dianox has developed a patented saliva diagnostics platform. Our first product is a broad range home test called Tell, which screens your hormones, vitamins, minerals and fats.We believe self-care is the most important aspect of health. Our company is dedicated to building better diagnostic tests to help people in their health journey. We arealways on the lookout for passionate partners in the health space. If you are excited about the potential of our work, please reach out via hello@dianox.com. | Non-equity Assistance / Jul 20, 2022 | ||
| KELLS is an AI-powered dental benefits platform designed to make oral care more accessible, affordable, and personalized. | Non-equity Assistance / Jun 01, 2022 | ||
| Patientory is empowering people to take charge of their own health. They’re revolutionizing the way doctors and patients interact and gain access to information, cutting out all layers and processes that currently are stumbling blocks in care coordination. They connect doctors, care providers, and consumers all within a single, secure platform –creating a care team that works together to provide the best care. | Seed / Nov 16, 2021 | ||
| Bristle analyzes oral microbiome to measure oral health status - including risk factors for cavities, gum disease, and bad breath - then provides personalized insights to optimize and maintain oral health. | Non-equity Assistance / Nov 16, 2021 | ||
| nQ Medical is a digital therapeutics company addressing neurocognitive and neuromotor disorder via 24/7, passive data collection via personal devices. It is a frictionless, non-invasive, early detection, remote disease progression monitoring, and therapeutic measurement modality. nQ uses an artificial intelligence company to developcomputational biomarkers that have been proven in five years of clinical trials to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders (Alzhemer's, Parkinson's, Multiple Sclerosis, ALS, concussion, et al. The platfomr focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians. nQ allows for early detection of disease, 24/7, passive, at home, remote monitoring of disease progression and the measurement of impact of therapy at a fraction of the cost of current gold standards. There is no required task. Just use your device as your would normally use it. Of note, as one of the company's medical advisors, Zoltan Mari, MD, of the Cleveland Clinic, so aptly quoted: "As important as it is to fund novel compounds for treating diseases, it is also important to set the stage for maximum impact when those compounds are discovered and approved for use. It is impossible to find a cure without early detection. That's why drug candidates fail. When the FDA puts its stamp on the first disease modifying drugs, such early detection technologies will be instantly necessary." He goes on to state further: "We also need a disease progression marker. Nothing so far has managed to do very well (while being profoundly expensive). Much of our research and clinical interest is turning toward disease progression. All efforts should focus on readying and perfecting early detection tools and building effective, reliable, inexpensive ways of tracking disease and the impact of therapy over time.” nQ is that early detection, disease progression computational biomarker. | Seed / Nov 16, 2021 | ||
| Health In Her HUE is a digital platform that connects Black women to Black and culturally competent healthcare providers, and offers evidence-based health content that centers Black women’s lived experiences. We strive to reduce racial health disparities by leveraging the power of technology, media and community to improve health outcomes for Blackwomen. | Pre-Seed / Nov 16, 2021 | ||
| Unfabled is a women’s health consumer platform that delivers curated and personalised solutions. | Grant / Nov 16, 2021 | ||
| Smilo.AI is an innovative app-based Oral Health solution using artificial intelligence and smartphone technology to identify as well as remotely monitor oral health diseases and design Smiles instantly with the click of a button anywhere anytime to build a patient-dentist relationship using our two-way communication. | Grant / Nov 16, 2021 | ||
| See all 12 investments → | |||
Co-Investors
About GSK NEXT
GSK NEXT is the strategic commercial growth engine for GSK Consumer Healthcare, focused on the creation and scaling of net-new product, service and platform businesses across everyday health.
GSK NEXT Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Malcolm Fogarty
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Nick Tate invest in?
Nick Tate invests primarily in Health Care, Dental and Wellness startups, most often at Seed and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nick Tate?
Public channels for Nick Tate include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nick Tate last invest?
The most recent investment recorded for Nick Tate closed in Dec 2022. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
